[go: up one dir, main page]

NO20061625L - Behandling og/eller forhindring av urininkontinens ved bruk av prolegemidler av gaba analoger - Google Patents

Behandling og/eller forhindring av urininkontinens ved bruk av prolegemidler av gaba analoger

Info

Publication number
NO20061625L
NO20061625L NO20061625A NO20061625A NO20061625L NO 20061625 L NO20061625 L NO 20061625L NO 20061625 A NO20061625 A NO 20061625A NO 20061625 A NO20061625 A NO 20061625A NO 20061625 L NO20061625 L NO 20061625L
Authority
NO
Norway
Prior art keywords
prodrugs
urinary incontinence
prevention
treatment
gaba analogues
Prior art date
Application number
NO20061625A
Other languages
English (en)
Inventor
Ronald William Barrett
Original Assignee
Xenopor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenopor Inc filed Critical Xenopor Inc
Publication of NO20061625L publication Critical patent/NO20061625L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Beskrevet heri er fremgangsmåten for anvendelse av prodrug av GABA-analoger og farmasøytiske sammensetninger derav for å behandle og/eller hindre urininkontinens hos mennesker, og farmasøytiske sammensetninger av prodrug av GABA-analoger anvendelige ved behandling og/eller hindring av urininkontinens.
NO20061625A 2003-09-11 2006-04-10 Behandling og/eller forhindring av urininkontinens ved bruk av prolegemidler av gaba analoger NO20061625L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US50258503P 2003-09-11 2003-09-11
US50521003P 2003-09-22 2003-09-22
US51228803P 2003-10-17 2003-10-17
US53874804P 2004-01-22 2004-01-22
PCT/US2004/029944 WO2005025562A1 (en) 2003-09-11 2004-09-13 Treating and/or preventing urinary incontinence using prodrugs of gaba analogs

Publications (1)

Publication Number Publication Date
NO20061625L true NO20061625L (no) 2006-06-12

Family

ID=34317683

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061625A NO20061625L (no) 2003-09-11 2006-04-10 Behandling og/eller forhindring av urininkontinens ved bruk av prolegemidler av gaba analoger

Country Status (11)

Country Link
US (2) US7700652B2 (no)
EP (1) EP1670451A4 (no)
JP (1) JP2007505149A (no)
KR (1) KR20060119971A (no)
AU (1) AU2004272111A1 (no)
CA (1) CA2537837A1 (no)
IL (1) IL174409A0 (no)
MX (1) MXPA06002731A (no)
NO (1) NO20061625L (no)
NZ (1) NZ545884A (no)
WO (1) WO2005025562A1 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
US7025745B2 (en) * 2002-10-07 2006-04-11 Advanced Cardiovascular Systems, Inc. Method of making a catheter balloon using a tapered mandrel
CA2537837A1 (en) 2003-09-11 2005-03-24 Xenoport, Inc. Treating and/or preventing urinary incontinence using prodrugs of gaba analogs
ATE516801T1 (de) * 2003-10-14 2011-08-15 Xenoport Inc Kristalline form eines gamma-aminobuttersäure- analogons
AU2005301970B2 (en) 2004-11-04 2011-06-02 Arbor Pharmaceuticals, Llc Gabapentin prodrug sustained release oral dosage forms
ES2646326T3 (es) 2005-08-03 2017-12-13 Sprout Pharmaceuticals, Inc. Uso de flibanserina en el tratamiento de la obesidad
EP1928450A2 (en) * 2005-08-26 2008-06-11 Xenoport, Inc. Treating premature ejaculation using gabapentin and pregabalin prodrugs
NL2000281C2 (nl) * 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
ATE456369T1 (de) * 2006-06-30 2010-02-15 Boehringer Ingelheim Int Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
WO2008073257A1 (en) * 2006-12-08 2008-06-19 Xenoport, Inc. Use of prodrugs of gaba analogs for treating diseases
US20080153888A1 (en) 2006-12-22 2008-06-26 Recordati Ireland Limited Alpha-2-delta ligand/nsaid therapeutic treatment of lower urinary tract disorders
CA2674610C (en) * 2007-01-11 2013-06-18 Xenoport, Inc. Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
EP2240158A2 (en) * 2007-12-28 2010-10-20 Intas Pharmaceuticals Limited Stabilized injectable formulation of pregabalin
EP2250148B1 (en) 2008-01-25 2016-08-17 XenoPort, Inc. Crystalline form of calcium-salts of (3s)-aminomethyl-5-methyl-hexanoic acids and methods of use
WO2009094577A2 (en) 2008-01-25 2009-07-30 Xenoport, Inc. Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use
TWI380812B (zh) * 2008-01-25 2013-01-01 Xenoport Inc （３ｓ）-胺甲基-５-甲基己酸前藥之晶形及使用方法
CA2686480A1 (en) 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts
JP2012519212A (ja) * 2009-03-03 2012-08-23 ゼノポート，インコーポレイティド Ｒ−バクロフェンプロドラッグの持効性放出経口投与形
US8377956B2 (en) 2010-03-01 2013-02-19 Xenoport, Inc. Use of (3R)-4-{[(1S)-2-methyl-1-(2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl) butanoic acid for treating urinary incontinence

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2996431A (en) 1953-12-16 1961-08-15 Barry Richard Henry Friable tablet and process for manufacturing same
US3402240A (en) 1957-06-25 1968-09-17 Pfizer & Co C Medicinal tablet and process of making same
US3139383A (en) 1961-06-26 1964-06-30 Norton Co Encapsulated time release pellets and method for encapsulating the same
US3962414A (en) 1972-04-27 1976-06-08 Alza Corporation Structured bioerodible drug delivery device
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3811444A (en) 1972-12-27 1974-05-21 Alza Corp Bioerodible ocular device
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
DE2336218C3 (de) 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
US3992518A (en) 1974-10-24 1976-11-16 G. D. Searle & Co. Method for making a microsealed delivery device
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4093709A (en) 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4079038A (en) 1976-03-05 1978-03-14 Alza Corporation Poly(carbonates)
US4066747A (en) 1976-04-08 1978-01-03 Alza Corporation Polymeric orthoesters housing beneficial drug for controlled release therefrom
US4070347A (en) 1976-08-16 1978-01-24 Alza Corporation Poly(orthoester) co- and homopolymers and poly(orthocarbonate) co- and homopolymers having carbonyloxy functionality
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4434153A (en) 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
US4421736A (en) 1982-05-20 1983-12-20 Merrel Dow Pharmaceuticals Inc. Sustained release diethylpropion compositions
US4721613A (en) 1982-12-13 1988-01-26 Alza Corporation Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use
US4820523A (en) 1986-04-15 1989-04-11 Warner-Lambert Company Pharmaceutical composition
US4752470A (en) 1986-11-24 1988-06-21 Mehta Atul M Controlled release indomethacin
US4816263A (en) 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine
US4853229A (en) 1987-10-26 1989-08-01 Alza Corporation Method for adminstering tiny pills
DE3928183A1 (de) 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
US5827819A (en) 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
WO1992009560A1 (en) 1990-11-27 1992-06-11 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
ES2165857T3 (es) 1992-05-20 2002-04-01 Univ Northwestern Analogos de gaba y acido l-glutamico para el tratamiento de trastornos del sistema nervioso central.
US6287598B1 (en) 1993-05-28 2001-09-11 Alza Corporation Method for providing sustained antiepileptic therapy
NZ326669A (en) 1996-02-07 2001-05-25 Warner Lambert Co Thiopyran or pyran derivatives useful as pharmaceutical agents
KR100487032B1 (ko) 1996-03-14 2005-12-21 워너-램버트 캄파니 엘엘씨 약제로서신규한브리지된시클릭아미노산
IL125544A (en) 1996-03-14 2002-03-10 Warner Lambert Co Transformed cyclic amino acids and pharmaceutical preparations containing them
US6375987B1 (en) 1996-10-01 2002-04-23 Gattefossé, S.A. Process for the manufacture of pharmaceutical composition with modified release of active principle comprising the matrix
DE69737719D1 (de) 1996-10-23 2007-06-21 Warner Lambert Co Substituierte gamma-aminobuttersäurederivate als arzneimittel
WO1999008670A1 (en) 1997-08-20 1999-02-25 Guglietta, Antonio Gaba analogs to prevent and treat gastrointestinal damage
US6635673B1 (en) 1997-10-27 2003-10-21 Warner-Lambert Company Cyclic amino acids and derivatives thereof useful as pharmaceutical agents
IL135314A0 (en) 1997-12-16 2001-05-20 Warner Lambert Co Novel amines as pharmaceutical agents
NZ503980A (en) 1997-12-16 2002-09-27 Warner Lambert Co 4(3)substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (= gabapentin analogues), pharmaceuticals thereof, and their use in the treatment of neurological disorders
ATE275552T1 (de) 1997-12-16 2004-09-15 Warner Lambert Co 1-substituierte-1-aminomethyl-cycloalkan derivate (= gabapentin analoga), deren herstellung und deren verwendung bei der behandlung von neurologischen erkrankungen
EP1082306A1 (en) 1998-05-26 2001-03-14 Warner-Lambert Company Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel
FR2779651B1 (fr) 1998-06-16 2001-04-20 Gattefosse Ets Sa Procede pour la fabrication de comprimes a liberation prolongee de principe(s) actif(s) presentant une cinetique de dissolution d'ordre zero
US6171615B1 (en) 1998-07-06 2001-01-09 Gattefoss{acute over (e)} Sustained release theophylline formulations, excipient systems and methods of production
CA2339273C (en) 1998-09-14 2005-10-18 Warner-Lambert Company Branched alkyl pyrrolidine-3-carboxylic acids
WO2000031020A1 (en) 1998-11-25 2000-06-02 Warner-Lambert Company Improved gamma amino butyric acid analogs
EP1031350A1 (en) 1999-02-23 2000-08-30 Warner-Lambert Company Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain
HUP0200738A3 (en) 1999-04-08 2003-03-28 Warner Lambert Co Method of the treatment of incontinence
US6992109B1 (en) * 1999-04-08 2006-01-31 Segal Catherine A Method for the treatment of incontinence
DE60034344T2 (de) * 1999-07-22 2008-01-10 University Of Rochester Methode zur behandlung der symptome hormoneller veränderungen, einschliesslich hitzewallungen
US6793934B1 (en) 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
GB2362646A (en) 2000-05-26 2001-11-28 Warner Lambert Co Cyclic amino acid derivatives useful as pharmaceutical agents
ES2300332T3 (es) 2000-06-26 2008-06-16 Warner-Lambert Company Llc Analogos de gabapentina para trastornos del sueño.
GB2365425A (en) 2000-08-01 2002-02-20 Parke Davis & Co Ltd Alkyl amino acid derivatives useful as pharmaceutical agents
WO2002032376A2 (en) 2000-10-06 2002-04-25 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
AU2002211863A1 (en) 2000-10-06 2002-04-15 Xenoport, Inc. Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
US7144877B2 (en) 2000-10-06 2006-12-05 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
US6683112B2 (en) * 2000-10-24 2004-01-27 Andrx Corporation Gabapentin prodrugs and formulations
GB2368579A (en) 2000-10-31 2002-05-08 Parke Davis & Co Ltd Azole pharmaceutical agents
AU2002239257A1 (en) 2000-11-17 2002-06-03 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
KR20070108282A (ko) 2001-06-11 2007-11-08 제노포트 인코포레이티드 감소된 독성을 가진 ｇａｂａ 유사체 프로드러그의 구강투여용 투여 형태물
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
AU2002316237A1 (en) 2001-06-13 2002-12-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt Use of the parathroid hormone-2 (pth2) receptor to screen for agents to treat pain
EP1438290B1 (en) 2001-08-09 2005-12-14 Eli Lilly And Company Cyclohept b!indole derivatives as spla2 inhibitors
EP1485082A4 (en) 2002-02-19 2009-12-30 Xenoport Inc PROCESS FOR THE SYNTHESIS OF PROMEDICAMENTS FROM 1-ACYL-ALKYL DERIVATIVES AND CORRESPONDING COMPOSITIONS
US7183259B2 (en) 2002-05-17 2007-02-27 Xenoport Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
WO2004053192A1 (en) 2002-12-11 2004-06-24 Xenoport, Inc. Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity
AU2003297927A1 (en) 2002-12-11 2004-06-30 Xenoport, Inc. Prodrugs of fused gaba analogs, pharmaceutical compositions and uses thereof
EP1480631B1 (en) 2002-12-20 2007-08-01 Dynogen Pharmaceuticals Inc. Methods of treating non-painful bladder disorders using alpha2-delta- subunit calcium channel modulators
PL378583A1 (pl) 2003-03-21 2006-05-02 Dynogen Pharmaceuticals, Inc. Sposoby leczenia zaburzeń dolnych dróg układu moczowego z zastosowaniem modulatorów mięśni gładkich i modulatorów podjednostki Ó2Ű kanałów wapniowych
US20040254246A1 (en) 2003-03-31 2004-12-16 Barrett Ronald W. Treating or preventing hot flashes using prodrugs of GABA analogs
US7662987B2 (en) 2003-07-15 2010-02-16 Xenoport, Inc. Methods for synthesis of acyloxyalkyl compounds
MXPA06001876A (es) 2003-08-20 2006-05-17 Xenoport Inc Prodrogas de aciloxialquil carbamato, metodos de sintesis y uso.
CA2537837A1 (en) 2003-09-11 2005-03-24 Xenoport, Inc. Treating and/or preventing urinary incontinence using prodrugs of gaba analogs
WO2005027850A2 (en) 2003-09-17 2005-03-31 Xenoport, Inc. Treating or preventing restless legs syndrome using prodrugs of gaba analogs
ATE516801T1 (de) 2003-10-14 2011-08-15 Xenoport Inc Kristalline form eines gamma-aminobuttersäure- analogons
US7227028B2 (en) 2003-12-30 2007-06-05 Xenoport, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
AU2005301970B2 (en) 2004-11-04 2011-06-02 Arbor Pharmaceuticals, Llc Gabapentin prodrug sustained release oral dosage forms
US20060222700A1 (en) 2005-04-05 2006-10-05 Groenewoud Pieter J Tablet and capsule form of liquid active ingredient
US20080292702A1 (en) 2005-12-16 2008-11-27 Hanmi Pharm. Co. Ltd. Solid Dispersion Comprising An Active Ingredient Having A Low Melting Point And Tablet For Oral Administration Comprising Same
CA2669246A1 (en) 2006-11-14 2008-05-22 Xenoport, Inc. Use of gabapentin and pregabalin prodrugs for treating tinnitus
WO2008073257A1 (en) 2006-12-08 2008-06-19 Xenoport, Inc. Use of prodrugs of gaba analogs for treating diseases
CA2674610C (en) 2007-01-11 2013-06-18 Xenoport, Inc. Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment

Also Published As

Publication number Publication date
KR20060119971A (ko) 2006-11-24
EP1670451A4 (en) 2009-10-21
WO2005025562A1 (en) 2005-03-24
AU2004272111A1 (en) 2005-03-24
US20100166825A1 (en) 2010-07-01
IL174409A0 (en) 2011-08-01
US7700652B2 (en) 2010-04-20
EP1670451A1 (en) 2006-06-21
JP2007505149A (ja) 2007-03-08
NZ545884A (en) 2010-01-29
CA2537837A1 (en) 2005-03-24
MXPA06002731A (es) 2006-06-05
US20050090550A1 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
NO20061625L (no) Behandling og/eller forhindring av urininkontinens ved bruk av prolegemidler av gaba analoger
WO2005027850A3 (en) Treating or preventing restless legs syndrome using prodrugs of gaba analogs
NO2020031I1 (no) kobimetinib, inklusive farmasøytisk akseptable salter og solvater, særlig kobimetinib hemifumarat
WO2006121861A3 (en) Biphenylazetidinone cholesterol absorption inhibitors
PL369108A1 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
PT2383271E (pt) Aminoquinolonas como inibidores de gsk-3
WO2007087468A3 (en) Adiponectin for treatment of various disorders
EA200601648A1 (ru) Глюкозамин и общие пролекарства глюкозамин/противовоспалительный агент, композиции и способы
DK2029602T3 (da) Triazolopyrazinforbindelser, der kan anvendes til behandling af degenerative og inflammatoriske sygdomme
WO2007133637A3 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
IL193252A0 (en) N-hydroxyacrylamide compounds
NO20081050L (no) Kaspaseinhibitor-prodroger
UA92636C2 (en) Tetrahydro-pyrimidoazepines as modulators of trpv1
WO2007100758A3 (en) Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
MX2009005114A (es) Uso de los profarmacos gabapentina y pregabalina para tratar el tinnitus.
NO20055000L (no) Fremgangsmate for a hindre varme oppblusinger ved anvendelse av prodrug av gaba-analoger
WO2007143557A3 (en) Compounds and methods for treating mammalian gastrointestinal parasitic infections
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
DK1648484T3 (da) Fremgangsmåde til behandling af arthritis-tilstande
WO2004043456A8 (en) Cholesterol absorption inhibitors for the treatment of demyelination
BRPI0506970A (pt) derivados de alfa-aminoamida úteis no tratamento de distúrbios do trato urinário inferior
WO2007028022A3 (en) Novel compounds as p2x7 modulators and uses thereof
WO2007027477A3 (en) Treating vulvodynia using prodrugs of gaba analogs
TW200716088A (en) Formulations and methods for treating amyloidosis
WO2008073779A3 (en) Compositions and methods for treating seizures

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application